BACKGROUND: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating inflammatory marker was available, this would be clinically valuable. AIM: To determine if levels of soluble CD163, a scavenger receptor shed by tissue macrophages, correlated with the inflammatory lesion in coeliac disease. METHODS: Serum samples were collected from 131 patients with untreated coeliac disease, 40 patients with treated coeliac disease, 92 non-coeliac disease control subjects and 131 healthy controls. A capture enzyme linked immunosorbance assay was established to measure levels of soluble CD163 in sera. The extent of the histological lesion in coeliac biopsies was assessed using a Marsh grading system. RESULTS: Levels of CD163 in untreated coeliac subjects were significantly elevated when compared with the treated coeliac patients, the disease control group and the healthy control subjects (P < 0.0001 in each instance). Moreover, coeliac patients with the most marked histological lesion (Marsh 3) had significantly higher levels of soluble CD163 than patients with Marsh grade 2 lesions (P < 0.0004), with grade 1 lesions (P < 0.0001) and grade 0 lesions (P < 0.0001). CONCLUSIONS: Measurement of soluble CD163 may be a useful method of monitoring the inflammatory lesion in coeliac disease.
BACKGROUND: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating inflammatory marker was available, this would be clinically valuable. AIM: To determine if levels of soluble CD163, a scavenger receptor shed by tissue macrophages, correlated with the inflammatory lesion in coeliac disease. METHODS: Serum samples were collected from 131 patients with untreated coeliac disease, 40 patients with treated coeliac disease, 92 non-coeliac disease control subjects and 131 healthy controls. A capture enzyme linked immunosorbance assay was established to measure levels of soluble CD163 in sera. The extent of the histological lesion in coeliac biopsies was assessed using a Marsh grading system. RESULTS: Levels of CD163 in untreated coeliac subjects were significantly elevated when compared with the treated coeliac patients, the disease control group and the healthy control subjects (P < 0.0001 in each instance). Moreover, coeliac patients with the most marked histological lesion (Marsh 3) had significantly higher levels of soluble CD163 than patients with Marsh grade 2 lesions (P < 0.0004), with grade 1 lesions (P < 0.0001) and grade 0 lesions (P < 0.0001). CONCLUSIONS: Measurement of soluble CD163 may be a useful method of monitoring the inflammatory lesion in coeliac disease.
Authors: Hugh James Freeman; Angeli Chopra; Michael Tom Clandinin; Alan Br Thomson Journal: World J Gastroenterol Date: 2011-05-14 Impact factor: 5.742
Authors: Emma Tippett; Wan-Jung Cheng; Clare Westhorpe; Paul U Cameron; Bruce J Brew; Sharon R Lewin; Anthony Jaworowski; Suzanne M Crowe Journal: PLoS One Date: 2011-05-20 Impact factor: 3.240
Authors: Vincent P O'Reilly; Limy Wong; Claire Kennedy; Louise A Elliot; Shane O'Meachair; Alice Marie Coughlan; Eoin C O'Brien; Michelle M Ryan; Diego Sandoval; Emma Connolly; Gerjan J Dekkema; Jiaying Lau; Wayel H Abdulahad; Jan-Stephan F Sanders; Peter Heeringa; Colm Buckley; Cathal O'Brien; Stephen Finn; Clemens D Cohen; Maja T Lindemeyer; Fionnuala B Hickey; Paul V O'Hara; Conleth Feighery; Sarah M Moran; George Mellotte; Michael R Clarkson; Anthony J Dorman; Patrick T Murray; Mark A Little Journal: J Am Soc Nephrol Date: 2016-03-03 Impact factor: 10.121
Authors: Gloria Serena; Daniel Huynh; Rosiane S Lima; Luciana M Vise; Rachel Freire; Laura Ingano; Maureen M Leonard; Stefania Senger; Alessio Fasano Journal: Front Nutr Date: 2019-11-05